fe disclaimer website uk with pi pd

This website has been developed and fully funded by Bayer for UK healthcare professionals and other relevant UK decision makers only.

Prescribing Information links and Adverse event reporting can be found at the bottom of the page.

Brand Navigation Banner Formulary

Bayer Logo Bayer Logo Bayer Logo

Providing medicines for
unmet needs

Helping you implement new and existing medicine policy


Formulary and support resources


This section and the resources available are designed to support you in your decision making and help you implement new and existing medicine policy.

Eylea 8mg Logo


Resources to support you with your decision making and implementation of EYLEA (aflibercept) 8 mg for the treatment of neovascular (wet) age-related macular degeneration in adults and the treatment of visual impairment due to diabetic macular oedema in adults.


EYLEA 8 mg represents a line extension from the currently available EYLEA 2 mg dose.

NICE has determined that a new technology appraisal is therefore not required.


As it is a line extension, implementation of EYLEA 8 mg may differ between local health systems. This page contains resources to support your formulary update activities across a range of likely scenarios:

Icon 1



Here you will find an interactive PDF based on the EYLEA 8 mg SMPC and further information on PHOTON and PULSAR trials and budgetary impact.

Icon 2



Abbreviated version for Line extension applications. This will also include budgetary impact information.


Icon 3



All of the information you might require regarding pack size, storage, how to use can be found here.


Reporting adverse events and quality complaints

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search MHRA Yellow Card in Google Play or Apple App Store.

Adverse events should also be reported to Bayer plc.

If you want to report an adverse event or quality complaint, reports can be directed to:

Tel: 01182 063500 or Email: pvuk@bayer.com

Further information is available on the "contact" tab at www.bayer.co.uk